A pilot study of circulating miR‑361-5p and miR-3125 in active tuberculosis patients in Babylon Province, Iraq
Article Main
Abstract
Tuberculosis (TB) remains a major global health challenge and is closely linked to host immune responses to Mycobacterium tuberculosis.MicroRNAs (miRNAs) have emerged as key post-transcriptional regulators of immune and inflammatory pathways and may serve as potential diagnostic biomarkers.This pilot study aimed to explore the diagnostic potential of serum miR-361-5p and miR-3125 in active pulmonary tuberculosis included 150 clinically suspected TB cases, of which 35 were laboratory-confirmed, along with 25 healthy controls. Diagnosis was performed using Acid-Fast Bacilli (AFB) smear microscopy (20.6% detection), Löwenstein–Jensen culture, and the GeneXpert MTB/RIF assay (23.3% detection). Serum levels of miR-361-5p and miR-3125 were measured by RT-qPCR and normalized using the 2^−ΔΔCt method. Both miRNAs were significant level upregulated in TB patients compared to controls. miR-361-5p levels were 6.73 ± 13.21 vs. 1.57 ± 1.7 (p = 0.0487), while miR-3125 levels were 3.48 ± 1.87 vs. 1.24 ± 0.62 (p < 0.0001). Median (IQR) values further supported these findings, particularly for miR-3125, which showed more consistent upregulation. ROC analysis demonstrated high diagnostic accuracy for miR-3125 (AUC = 0.92, sensitivity = 89%, specificity=79%), whereas miR-361-5p showed limited performance (AUC = 0.547). Additionally, miR-3125 levels were significantly higher in rifampicin-resistant patients than in sensitive cases (4.92 ± 2.1 vs. 3.12 ± 1.7; p = 0.007), where miR-361-5p showed no significant association. This pilot study shows that serum miR-361-5p and miR-3125 are elevated in active TB, with miR-3125 potentially serving as a biomarker for rifampicin resistance, indicating it could be useful as a non-invasive tool for early TB detection.
Article Details
Article Details
Biomarkers, Mycobacterium tuberculosis, microRNA-361-5p, microRNA-3125, Tuberculosis
Agrawal, P., Upadhyay, A. & Kumar, A. (2024). MicroRNA as biomarkers in tuberculosis: A new emerging molecular diagnostic solution. Diagnostic Microbiology andInfectiousDisease,108(1),116082.https://doi.org/10.1016/j.diagmicrobio.2023.1160 82
Chen, H. K., Lin, C. X., Lv, P. L., Li, W. F., Feng, Y. Y., Deng, X. J., … & Guo, X. G. (2023). Xpert MTB/RIF assay for the diagnosis of pulmonary tuberculosis based on bronchoalveolar lavage fluid: A systematic review and meta-analysis. Infectious Microbes & Diseases, 5(3), 111–119. https://doi.org/10.1097/IM9.0000000000000122
Davidson, G., Davidson, D. U., Okoye, O. K., Mensah, L. S., Ukaegbu, E. C., Agbor, D. B. A., … & Uche, C. J. (2024). Overview of tuberculosis: Causes, symptoms and risk factors. Asian Journal of Research in Infectious Diseases, 15(9), 8–19. https://doi.org/10.9734/ajrid/2024/v15i9370
de Santana Silva, Í. T. S., Fehlberg, H. F., Ferreira, F. B., da Silva, M. F., Dos Santos, P. R., Porto, V. M., … & Kaneto, C. M. (2025). Identification of SnRNA U6 as an endogenous reference gene for normalization of miRNA expression data in COVID-19 patients. Scientific Reports, 15(1), 26636. https://doi.org/10.1038/s41598-025-26636-0
Draz, N. I., El Hady, S. A., Elsayed, M. S., Korraa, E. E. A. & El Magd, N. M. (2014). Serum microRNA 29a and microRNA 361‑5p as potential diagnostic biomarkers for active pulmonary tuberculosis. Egyptian Journal of Medical Microbiology, 23(3), 170–177. https://doi.org/10.21608/ejmm.2014.114320
Ergin, K. & Çetinkaya, R. (2022). Regulation of microRNAs. Methods in Molecular Biology, 2257, 1–32. https://doi.org/10.1007/978-1-0716-1170-8_1
Feng, G., Jiang, H. & Chen, Y. (2025). Efficacy of Xpert MTB/RIF assay in detecting Mycobacterium tuberculosis in samples with different results by smear and culture in a coastal city with high incidence of tuberculosis. BMC Infectious Diseases, 25(1), Article 55. https://doi.org/10.1186/s12879-025-10446-z
Fu, Y., Yi, Z., Wu, X., Li, J. & Xu, F. (2011). Circulating microRNAs in patients with active pulmonary tuberculosis. Journal of Clinical Microbiology, 49(12), 4246–4251. https://doi.org/10.1128/JCM.01349-11
Han, M., Chen, Z., He, P., Li, Z., Chen, Q., Tong, Z., … & Zhang, H. (2022). YgiM may act as a trigger in sepsis caused by Klebsiella pneumoniae through the membrane-associated ceRNA network. Frontiers in Genetics, 13, 973145. https://doi.org/10.3389/fgene.2022.973145
Harapan, H., Anwar, H. & Haryanto, S. (2013). Diagnostic potential of circulating microRNAs in tuberculosis: A systematic review and metaanalysis. Infection, Genetics and Evolution, 19, 186–195. https://doi.org/10.1016/j.meegid.2013.06.004
Islam, M. M., Alam, M. S., Liu, Z., Khatun, M. S., Yusuf, B., Hameed, H. M. A., Tian, X., Chhotaray, C., Basnet, R. & Abraha, H. (2024). Molecular mechanisms of resistance and treatment efficacy of clofazimine and bedaquiline against Mycobacterium tuberculosis. Frontiers in Medicine, 10, 1304857. https://doi.org/10.3389/fmed.2024.1304857
Kimura, M., Kothari, S., Gohir, W., Camargo, J. F. & Husain, S. (2023). MicroRNAs in infectious diseases: potential diagnostic biomarkers and therapeutic targets. Clinical Microbiology Reviews, 36(4), e00015-23. https://doi.org/10.1128/CMR.00015-23
Mehta, P. (2021). MicroRNA research: The new dawn of Tuberculosis. The Indian Journal of Tuberculosis, 68(3), 321–329. https://doi.org/10.1016/j.ijtb.2020.11.011
Mohammadnabi, N., Shamseddin, J., Emadi, M., Bodaghi, A. B., Varseh, M., Shariati, A., … & Farahani, A. (2024). Mycobacterium tuberculosis: The mechanism of pathogenicity, immune responses, and diagnostic challenges. Journal of Clinical Laboratory Analysis, 38(23), e25122. https://doi.org/10.1002/jcla.25122
Mohammed, K. A. S., Khudhair, G. S. & Al Rabeai, D. B. (2022). Prevalence and drug resistance pattern of Mycobacterium tuberculosis isolated from tuberculosis patients in Basra, Iraq. Polish Journal of Microbiology, 71(2), 205–215. https://doi.org/10.33073/pjm-2022-018
Musuenge, B. B., Kayembe, J. M., Numbi, O. L. & Longo-Mbenza, B. (2020). Nutritional status of patients with tuberculosis and associated factors. Nutrients, 12(9), 2540. https://doi.org/10.3390/nu12092540
Peer, V., Schwartz, N. & Green, M. S. (2023). Gender differences in tuberculosis incidence rates—A pooled analysis of data from seven high-income countries by age group and time period. Frontiers in Public Health, 10, 997025. https://doi.org/10.3389/fpubh.2022.997025
Qi, Y., Cui, L., Ge, Y., Shi, Z., Zhao, K., Guo, X., … & Lu, Z. (2012). Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infectious Diseases, 12(1), 384. https://doi.org/10.1186/1471-2334-12-384
Sabir, N., Firaq, T. F., Adnan, N. A. & Riana, H. (2018). Serum microRNA expression profiling in tuberculosis patients: Promising biomarkers for diagnosis. Microbial Pathogenesis, 116, 227–233. https://doi.org/10.1016/j.micpath.2018.04.041
Sarkar, M. & Sarkar, J. (2025). Transmission of Mycobacterium tuberculosis. The Journal of the Association of Physicians of India, 73(9), 91–96. https://doi.org/10.59556/japi.73.1113
Sinigaglia, A., Peta, E., Riccetti, S., Venkateswaran, S., Manganelli, R. & Barzon, L. (2020). Tuberculosis-associated microRNAs: From pathogenesis to disease biomarkers. Cells, 9(10), 2160. https://doi.org/10.3390/cells9102160
Wang, L., Xiong, Y., Fu, B., Guo, D., Zaky, M. Y., Lin, X. & Wu, H. (2022). MicroRNAs as immune regulators and biomarkers in tuberculosis. Frontiers in Immunology, 13, Article 1027472. https://doi.org/10.3389/fimmu.202 2.1027472
World Health Organization. (2024). WHO consolidated guidelines on tuberculosis. Module 6: Tuberculosis and comorbidities. World Health Organization. https://www.who.int/publications/i/item/9789240072343
Wu, M., Li, G., Wang, W. & Ren, H. (2023). Emerging roles of microRNAs in septic cardiomyopathy. Frontiers in Pharmacology, 14, 1181372. https://doi.org/10.3389/fphar.2023.1181372
Yan, J., Zhang, N., Qi, C., Liu, X. & Shangguan, D. (2013). One-step real-time RT-PCR for detection of microRNAs. Talanta, 110, 190–195. https://doi.org/10.1016/j.talanta.2013.01.023
Zaporojan, N., Negrean, R. A., Hodișan, R., Zaporojan, C., Csep, A. & Zaha, D. C. (2024). Evolution of laboratory diagnosis of tuberculosis. Clinics and Practice, 14(2), 388–416. https://doi.org/10.3390/clinpract14020030
Zhang, Y., Zhang, L., Shi, L., Wei, L., Gan, L., Hu, Y., Huang, H., Xie, K., Jiang, T. & Li, J.-C. (2025). Plasma exosomal miR‑122‑5p_R1, miR‑23b‑3p_R+1, and miR‑15a‑5p_R1 are associated with multidrug resistant tuberculosis. BMC Infectious Diseases, 25(1), 1063. https://doi.org/10.1186/s12879-025-11487-0
Zhou, X., Li, X. & Wu, M. (2018). miRNAs reshape immunity and inflammatory responses in bacterial infection. Signal Transduction and Targeted Therapy, 3(1), 14. https://doi.org/10.1038/s41392-018-0014-7
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This work is licensed under Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) © Author (s)
